Révisions pour triplepharm webarchive CDX

Télécharger en ZIP

d13forme a révisé ce gist 1751930342. Aller à la révision

Aucun changement

d13forme a révisé ce gist 1751929949. Aller à la révision

3 files changed, 0 insertions, 0 deletions

amass_scan_tripleharm_by.txt renommé en amass_scan_triplepharm_by.txt

Fichier renommé sans modifications

links_en_tripleharm_by_WACDX.txt renommé en links_en_triplepharm_by_WACDX.txt

Fichier renommé sans modifications

links_tripleharm_by_WACDX.txt renommé en links_triplepharm_by_WACDX.txt

Fichier renommé sans modifications

d13forme a révisé ce gist 1751925054. Aller à la révision

1 file changed, 47 insertions

links_en_tripleharm_by_WACDX.txt(fichier créé)

		@@ -0,0 +1,47 @@
1	+	https://en.triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
2	+	https://en.triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
3	+	https://en.triplepharm.by/assets/files/antibiotikorezistentnost_eng.pdf
4	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/Dorenem-instr.PDF
5	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/Dorenem-instr.PDF
6	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/IMP-Kolistat-avg2016.PDF
7	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/IMP-Kolistat-avg2016.PDF
8	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-imicinem.PDF
9	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-imicinem.PDF
10	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-Tejkoplanin-2017.PDF
11	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/instrukciya-Tejkoplanin-2017.PDF
12	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/Instrukciya-Vankomicin.pdf
13	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/Instrukciya-Vankomicin.pdf
14	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/Meropenem-instr.PDF
15	+	https://en.triplepharm.by/assets/files/instrukciya-new-rus/Meropenem-instr.PDF
16	+	https://en.triplepharm.by/assets/files/kolistin-u-detej-s-MV_eng.pdf
17	+	https://en.triplepharm.by/assets/files/new-instr/dorenem-500-mg-dlya-infuzij.pdf
18	+	https://en.triplepharm.by/assets/files/new-instr/dorenem-500-mg-dlya-infuzij.pdf
19	+	https://en.triplepharm.by/assets/files/new-instr/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
20	+	https://en.triplepharm.by/assets/files/new-instr/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
21	+	https://en.triplepharm.by/assets/files/new-instr/imp-fosfomicin-tf.pdf
22	+	https://en.triplepharm.by/assets/files/new-instr/imp-fosfomicin-tf.pdf
23	+	https://en.triplepharm.by/assets/files/new-instr/imp_fosfomicin-tf-ing.pdf
24	+	https://en.triplepharm.by/assets/files/new-instr/imp_fosfomicin-tf-ing.pdf
25	+	https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-dlya-ingalyacij.pdf
26	+	https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-dlya-ingalyacij.pdf
27	+	https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
28	+	https://en.triplepharm.by/assets/files/new-instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
29	+	https://en.triplepharm.by/assets/files/new-instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
30	+	https://en.triplepharm.by/assets/files/new-instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
31	+	https://en.triplepharm.by/assets/files/new-instr/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
32	+	https://en.triplepharm.by/assets/files/new-instr/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
33	+	https://en.triplepharm.by/assets/files/new-instr/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
34	+	https://en.triplepharm.by/assets/files/new-instr/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
35	+	https://en.triplepharm.by/assets/files/new-instr/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
36	+	https://en.triplepharm.by/assets/files/new-instr/vankomicin-500-1000-dlya-infuzij.pdf
37	+	https://en.triplepharm.by/assets/files/new-instr/vankomicin-500-1000-dlya-infuzij.pdf
38	+	https://en.triplepharm.by/assets/files/new/instrukciya-klaribakcin-en.pdf
39	+	https://en.triplepharm.by/assets/files/new/instrukciya-klaribakcin-en.pdf
40	+	https://en.triplepharm.by/assets/files/new/klaribakcin.pdf
41	+	https://en.triplepharm.by/assets/files/new/klaribakcin.pdf
42	+	https://en.triplepharm.by/assets/files/polimiksini_eng.pdf
43	+	http://en.triplepharm.by:80/assets/files/Primenenie-Tejkoplanina-TF-u-detej_eng.pdf
44	+	https://en.triplepharm.by/assets/files/Primenenie-Tejkoplanina-TF_eng(1).pdf
45	+	https://en.triplepharm.by/politika-pers.pdf
46	+	https://en.triplepharm.by/politika-pers.pdf
47	+	https://en.triplepharm.by/politika-pers.pdf

d13forme a révisé ce gist 1751777670. Aller à la révision

2 files changed, 331 insertions

amass_scan_tripleharm_by.txt(fichier créé)

		@@ -0,0 +1,49 @@
1	+	triplepharm.by (FQDN) --> mx_record --> mail.triplepharm.by (FQDN)
2	+	mail.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress)
3	+	93.84.0.0/15 (Netblock) --> contains --> 93.84.97.177 (IPAddress)
4	+	6697 (ASN) --> managed_by --> BELPAK-AS BELPAK, BY (RIROrganization)
5	+	6697 (ASN) --> announces --> 93.84.0.0/15 (Netblock)
6	+	triplepharm.by (FQDN) --> ns_record --> ns2.hoster.by (FQDN)
7	+	triplepharm.by (FQDN) --> ns_record --> ns1.hoster.by (FQDN)
8	+	triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
9	+	triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
10	+	autodiscover.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress)
11	+	www.en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
12	+	www.en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
13	+	2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:7::84:12e (IPAddress)
14	+	93.125.99.0/24 (Netblock) --> contains --> 93.125.99.66 (IPAddress)
15	+	6697 (ASN) --> announces --> 2a0a:7d80::/47 (Netblock)
16	+	6697 (ASN) --> announces --> 93.125.99.0/24 (Netblock)
17	+	ftp.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
18	+	ftp.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
19	+	localhost.triplepharm.by (FQDN) --> a_record --> 127.0.0.1 (IPAddress)
20	+	localhost.triplepharm.by (FQDN) --> aaaa_record --> ::1 (IPAddress)
21	+	127.0.0.0/8 (Netblock) --> contains --> 127.0.0.1 (IPAddress)
22	+	::/127 (Netblock) --> contains --> ::1 (IPAddress)
23	+	0 (ASN) --> managed_by --> Not routed (RIROrganization)
24	+	0 (ASN) --> managed_by --> Reserved Network Address Blocks (RIROrganization)
25	+	0 (ASN) --> announces --> 127.0.0.0/8 (Netblock)
26	+	0 (ASN) --> announces --> ::/127 (Netblock)
27	+	en.triplepharm.by (FQDN) --> mx_record --> mailbe05.hoster.by (FQDN)
28	+	ns1.hoster.by (FQDN) --> a_record --> 93.125.30.200 (IPAddress)
29	+	ns1.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1::6:0 (IPAddress)
30	+	en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
31	+	en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
32	+	93.125.30.0/23 (Netblock) --> contains --> 93.125.30.200 (IPAddress)
33	+	2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1::6:0 (IPAddress)
34	+	6697 (ASN) --> announces --> 93.125.30.0/23 (Netblock)
35	+	ns2.hoster.by (FQDN) --> a_record --> 185.179.82.104 (IPAddress)
36	+	ns2.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:3:1::8 (IPAddress)
37	+	_autodiscover._tcp.triplepharm.by (FQDN) --> srv_record --> mail.triplepharm.by (FQDN)
38	+	185.179.82.0/23 (Netblock) --> contains --> 185.179.82.104 (IPAddress)
39	+	2a0a:7d80:3::/48 (Netblock) --> contains --> 2a0a:7d80:3:1::8 (IPAddress)
40	+	12406 (ASN) --> managed_by --> BN-AS Belarussian data communication service provider. (RIROrganization)
41	+	12406 (ASN) --> announces --> 185.179.82.0/23 (Netblock)
42	+	35594 (ASN) --> managed_by --> TUTBY-AS (RIROrganization)
43	+	35594 (ASN) --> announces --> 2a0a:7d80:3::/48 (Netblock)
44	+	177.97.84.93.in-addr.arpa (FQDN) --> ptr_record --> mail.triplepharm.by (FQDN)
45	+	mailbe05.hoster.by (FQDN) --> a_record --> 93.125.31.215 (IPAddress)
46	+	mailbe05.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress)
47	+	93.125.30.0/23 (Netblock) --> contains --> 93.125.31.215 (IPAddress)
48	+	2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress)
49	+	ipv6.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)

links_tripleharm_by_WACDX.txt(fichier créé)

		@@ -0,0 +1,282 @@
1	+	https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf
2	+	https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf
3	+	https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
4	+	https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
5	+	https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
6	+	https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
7	+	https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
8	+	https://triplepharm.by/assets/files/0305instr/dorenem.pdf
9	+	https://triplepharm.by/assets/files/0305instr/dorenem.pdf
10	+	https://triplepharm.by/assets/files/0305instr/dorenem.pdf
11	+	https://triplepharm.by/assets/files/0305instr/imicinem.pdf
12	+	https://triplepharm.by/assets/files/0305instr/imicinem.pdf
13	+	https://triplepharm.by/assets/files/0305instr/imicinem.pdf
14	+	https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
15	+	https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
16	+	https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
17	+	https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
18	+	https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
19	+	https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
20	+	https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
21	+	https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
22	+	https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
23	+	https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
24	+	https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
25	+	https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
26	+	https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
27	+	https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
28	+	https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
29	+	https://triplepharm.by/assets/files/0305instr/meropenem.pdf
30	+	https://triplepharm.by/assets/files/0305instr/meropenem.pdf
31	+	https://triplepharm.by/assets/files/0305instr/meropenem.pdf
32	+	https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
33	+	https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
34	+	https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
35	+	https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
36	+	https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
37	+	https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
38	+	https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
39	+	https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
40	+	https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
41	+	https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
42	+	http://triplepharm.by:80/assets/files/1.pdf
43	+	http://triplepharm.by:80/assets/files/1.pdf
44	+	http://triplepharm.by:80/assets/files/1.pdf
45	+	http://triplepharm.by:80/assets/files/1.pdf
46	+	http://www.triplepharm.by:80/assets/files/1.pdf
47	+	http://triplepharm.by/assets/files/1.pdf
48	+	http://triplepharm.by/assets/files/1.pdf
49	+	http://triplepharm.by/assets/files/1.pdf
50	+	https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
51	+	https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
52	+	https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
53	+	https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf
54	+	https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf
55	+	https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
56	+	https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
57	+	https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
58	+	http://triplepharm.by:80/assets/files/annot-bronhomoss-utverzh_eng.pdf
59	+	http://triplepharm.by:80/assets/files/annot-fitokordium-utverzh_eng.pdf
60	+	http://triplepharm.by:80/assets/files/annot-gastroforte-utverzh_eng.pdf
61	+	http://triplepharm.by:80/assets/files/annot-sedakalm-utverzh_eng.pdf
62	+	http://triplepharm.by:80/assets/files/annot-sinu-fito-utverzh_eng.pdf
63	+	http://triplepharm.by:80/assets/files/annot-sinu-kapli-utverzh_eng.pdf
64	+	http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf
65	+	http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf
66	+	http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
67	+	http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
68	+	https://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
69	+	http://www.triplepharm.by:80/assets/files/Brinamid_eng.pdf
70	+	http://triplepharm.by:80/assets/files/bronhomoss-annot.pdf
71	+	http://triplepharm.by:80/assets/files/fitokordium-annot.pdf
72	+	http://triplepharm.by:80/assets/files/gastroforte-annot.pdf
73	+	http://triplepharm.by:80/assets/files/gastroforte-annot.pdf
74	+	http://triplepharm.by/assets/files/IMP-Kolistat-avg2016.PDF
75	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/Dorenem-instr.PDF
76	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Klaribakcin.pdf
77	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Kolistat-avg2016.PDF
78	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefepim.PDF
79	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefosulbaktam.PDF
80	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-imicinem.PDF
81	+	http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
82	+	http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
83	+	http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
84	+	http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna.PDF
85	+	http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
86	+	http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
87	+	http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
88	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-Tejkoplanin-2017.PDF
89	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-triksocef(14.07.2017).pdf
90	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Vankomicin.pdf
91	+	https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
92	+	https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
93	+	https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
94	+	https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
95	+	https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
96	+	https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
97	+	http://www.triplepharm.by/assets/files/insruktiya-new-rus/Meropenem-instr.PDF
98	+	http://triplepharm.by/assets/files/instr-kolistat-eng(1).pdf
99	+	http://triplepharm.by:80/assets/files/instr-kolistat-eng.pdf
100	+	http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf
101	+	http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf
102	+	http://triplepharm.by/assets/files/Instruction_Benustin_eng.pdf
103	+	http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf
104	+	http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf
105	+	http://triplepharm.by/assets/files/Instrukciya-Benustin.PDF
106	+	http://www.triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF
107	+	http://triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF
108	+	http://triplepharm.by:80/assets/files/instrukciya-cefepim-2015.pdf
109	+	http://triplepharm.by:80/assets/files/instrukciya-cefepim.PDF
110	+	http://triplepharm.by:80/assets/files/instrukciya-cefosulbaktam.pdf
111	+	http://triplepharm.by:80/assets/files/instrukciya-dorenem(1).pdf
112	+	http://triplepharm.by:80/assets/files/instrukciya-dorenem_eng.pdf
113	+	http://triplepharm.by:80/assets/files/instrukciya-imicinem.PDF
114	+	http://triplepharm.by:80/assets/files/instrukciya-imipenem-2015.pdf
115	+	http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
116	+	http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
117	+	http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
118	+	http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
119	+	http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
120	+	http://triplepharm.by:80/assets/files/instrukciya-kapreocin(1).PDF
121	+	https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
122	+	https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
123	+	https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
124	+	http://triplepharm.by:80/assets/files/instrukciya-kapreocin-angl.pdf
125	+	https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
126	+	http://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
127	+	https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
128	+	https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
129	+	http://www.triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
130	+	https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
131	+	https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
132	+	https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
133	+	http://triplepharm.by:80/assets/files/instrukciya-kolistat(1).PDF
134	+	http://triplepharm.by:80/assets/files/instrukciya-Meropenem(1).pdf
135	+	http://triplepharm.by:80/assets/files/instrukciya-Triksocef_eng.pdf
136	+	http://triplepharm.by:80/assets/files/instrukciya-vankomicin(1).pdf
137	+	http://triplepharm.by:80/assets/files/instrukciya-vankomicin_eng.pdf
138	+	http://triplepharm.by:80/assets/files/InstrukciyaCefosulb-na-utv-----(1).pdf
139	+	http://triplepharm.by:80/assets/files/InstrukciyaMeropenem.pdf
140	+	http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf
141	+	http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf
142	+	http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf
143	+	http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf
144	+	http://triplepharm.by:80/assets/files/lechenie-sinegnojnoj-infekcii.pdf
145	+	https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
146	+	https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
147	+	https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
148	+	https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
149	+	https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
150	+	https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
151	+	https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
152	+	https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
153	+	https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
154	+	https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
155	+	https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
156	+	https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
157	+	https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
158	+	https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
159	+	https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
160	+	https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf
161	+	https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf
162	+	http://triplepharm.by/assets/files/Saj-InstrukciyaPaulina_eng.pdf
163	+	http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
164	+	http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
165	+	http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
166	+	http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
167	+	http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
168	+	http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
169	+	http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
170	+	http://www.triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
171	+	http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
172	+	http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
173	+	http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
174	+	http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
175	+	http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
176	+	http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
177	+	http://www.triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
178	+	http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
179	+	http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
180	+	http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
181	+	http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
182	+	http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
183	+	http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
184	+	http://triplepharm.by:80/assets/files/sedakalm-annot.pdf
185	+	http://triplepharm.by:80/assets/files/sinu-fito-annot.pdf
186	+	http://triplepharm.by:80/assets/files/sinu-kapli-annot.pdf
187	+	http://www.triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf
188	+	http://triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf
189	+	http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
190	+	http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
191	+	http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
192	+	http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
193	+	https://triplepharm.by/assets/files/tejkoplanin--tf-3.pdf
194	+	https://triplepharm.by/att1.pdf
195	+	https://triplepharm.by/att1.pdf
196	+	https://triplepharm.by/att1.pdf
197	+	https://triplepharm.by/licenziya.pdf
198	+	https://triplepharm.by/licenziya.pdf
199	+	https://triplepharm.by/licenziya.pdf
200	+	https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf
201	+	https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf
202	+	https://triplepharm.by/pdf/%D0%9F%D0%BE%D0%BB%D1%83%D0%B0%D0%B2%D1%82%D0%BE%D0%BC%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F%20%D0%BE%D0%B1%D0%BA%D0%B0%D1%82%D0%BA%D0%B0.pdf
203	+	https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf
204	+	https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf
205	+	https://triplepharm.by/pdf/3-samson.pdf
206	+	https://triplepharm.by/pdf/4-tapalskij.pdf
207	+	https://triplepharm.by/pdf/4-tapalskij.pdf
208	+	https://triplepharm.by/politika-pers.pdf
209	+	https://triplepharm.by/politika-pers.pdf
210	+	https://triplepharm.by/politika-pers.pdf
211	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP-EAES.pdf
212	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP.pdf
213	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/dorenem.pdf
214	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/ertapenem.pdf
215	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-2g.pdf
216	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-5g.pdf
217	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/imicinem.pdf
218	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/klaribakcin.pdf
219	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-1-mln.pdf
220	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-2-mln.pdf
221	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-3-mln-i-4-5-mln.pdf
222	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/licenziya.pdf
223	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/meropenem.pdf
224	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/partners.pdf
225	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/policy.pdf
226	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/tejkoplanin.pdf
227	+	https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/vankomicin.pdf
228	+	https://triplepharm.by/wp-content/uploads/1-doriprem.pdf
229	+	https://triplepharm.by/wp-content/uploads/10-article.pdf
230	+	https://triplepharm.by/wp-content/uploads/13-article.pdf
231	+	https://triplepharm.by/wp-content/uploads/2-article.pdf
232	+	https://triplepharm.by/wp-content/uploads/3-article.pdf
233	+	https://triplepharm.by/wp-content/uploads/4-article.pdf
234	+	https://triplepharm.by/wp-content/uploads/5-article.pdf
235	+	https://triplepharm.by/wp-content/uploads/6-article.pdf
236	+	https://triplepharm.by/wp-content/uploads/7-article.pdf
237	+	https://triplepharm.by/wp-content/uploads/9-article.pdf
238	+	https://triplepharm.by/wp-content/uploads/certificatgmp-eaes2025.pdf
239	+	https://triplepharm.by/wp-content/uploads/certificatgmp2025.pdf
240	+	https://triplepharm.by/wp-content/uploads/dorenem.pdf
241	+	https://triplepharm.by/wp-content/uploads/dorenem_en.pdf
242	+	https://triplepharm.by/wp-content/uploads/ertapenem.pdf
243	+	https://triplepharm.by/wp-content/uploads/ertapenem_en.pdf
244	+	https://triplepharm.by/wp-content/uploads/fosfomicin-2g.pdf
245	+	https://triplepharm.by/wp-content/uploads/fosfomicin-5g.pdf
246	+	https://triplepharm.by/wp-content/uploads/fosfomicin_en.pdf
247	+	https://triplepharm.by/wp-content/uploads/imicinem.pdf
248	+	https://triplepharm.by/wp-content/uploads/imicinem_en.pdf
249	+	https://triplepharm.by/wp-content/uploads/klaribakcin.pdf
250	+	https://triplepharm.by/wp-content/uploads/klaribakcin_en.pdf
251	+	https://triplepharm.by/wp-content/uploads/kolistat-1-mln.pdf
252	+	https://triplepharm.by/wp-content/uploads/kolistat-2-mln.pdf
253	+	https://triplepharm.by/wp-content/uploads/kolistat-2-mln_en.pdf
254	+	https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln.pdf
255	+	https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln_en.pdf
256	+	https://triplepharm.by/wp-content/uploads/licenziya.pdf
257	+	https://triplepharm.by/wp-content/uploads/meropenem.pdf
258	+	https://triplepharm.by/wp-content/uploads/meropenem_en.pdf
259	+	https://triplepharm.by/wp-content/uploads/partners.pdf
260	+	https://triplepharm.by/wp-content/uploads/policy.pdf
261	+	https://triplepharm.by/wp-content/uploads/reprint_patogen-speczifichnaya-terapiya-1.pdf
262	+	https://triplepharm.by/wp-content/uploads/tejkoplanin.pdf
263	+	https://triplepharm.by/wp-content/uploads/tejkoplanin_en.pdf
264	+	https://triplepharm.by/wp-content/uploads/vankomicin.pdf
265	+	https://triplepharm.by/wp-content/uploads/vankomicin_en.pdf
266	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
267	+	http://triplepharm.by/assets/files/anketa_soiskatelya_tnk(2).doc
268	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
269	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
270	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
271	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
272	+	http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
273	+	http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
274	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
275	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
276	+	http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
277	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
278	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
279	+	http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
280	+	http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
281	+	http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
282	+	http://triplepharm.by/123.rtf

Plus récent Plus ancien